Pemphigus
Frank Santoro(Philadelphia VA Medical Center), Victoria P. Werth(Philadelphia VA Medical Center), Eric T. Stoopler(University of Pennsylvania)
Cited by 68
Related Papers
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|586
Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
|Journal of the American Academy of Dermatology|2011|370
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|246
Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus
|Journal of Investigative Dermatology|2009|238
Interventions for pemphigus vulgaris and pemphigus foliaceus
|Cochrane Database of Systematic Reviews|2009|184